Skip to main content

Table 7 Supportive therapy

From: Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]

  Number of patients (%)
Cycle 1 (intravenously) DD/DI arm (N = 86) HDI arm (N = 80)
Paracetamol 79 (92) 71 (89)
Anti-emetics 47 (55) 44 (55)
Anti-diarrhea 3 (3) 2 (2)
Anti-anxiety 20 (23) 15 (19)
Vitamin 22 (26) 15 (19)
Subsequent cycles DD/DI arm (N = 71) HDI arm (N = 69)
Paracetamol 64 (90) 55 (80)
Anti-emetics 44 (62) 21 (30)
Anti-diarrhea 6 (8) 2 (3)
Anti-anxiety 19 (27) 16 (23)
Vitamin 21 (30) 18 (26)